Corbus Pharmaceuticals Holdings (CRBP) Hisse Özeti

Klinik aşamada bir şirket olan Corbus Pharmaceuticals Holdings, Inc. kanser ve obezite için terapötikler geliştirmekte ve ticarileştirmektedir. Daha fazla detay

CRBP temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	2/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Ödüller

Gelirin yılda 76.72% oranında artması öngörülüyor

Risk Analizi

Geliri 1 milyon ABD dolarından az ( $0 )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Son 3 ayda önemli miktarda içeriden satış gerçekleşti

+ 1 daha fazla risk

CRBP Community Fair Values

Create Narrative

See what 10 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Corbus Pharmaceuticals Holdings, Inc. Rakipler

Fiyat Geçmişi ve Performans

Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Corbus Pharmaceuticals Holdings
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$7.91
52 Haftanın En Yüksek Seviyesi	US$20.56
52 Haftanın En Düşük Seviyesi	US$6.72
Beta	2.68
1 Aylık Değişim	-19.45%
3 Aylık Değişim	-7.70%
1 Yıllık Değişim	6.60%
3 Yıllık Değişim	-19.70%
5 Yıllık Değişim	-86.68%
Halka arzdan bu yana değişim	-91.21%

Son Haberler & Güncellemeler

Analiz Makalesi • May 20

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Recent updates

Analiz Makalesi • May 20

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although...

Seeking Alpha • Feb 06

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Summary Corbus Pharmaceuticals maintains a 'Hold' rating as it advances CRB-701 for HNSCC and CRB-913 for obesity. CRBP expects to initiate a registrational CRB-701 study in mid-2026 and release 12-week CRB-913 obesity data in summer 2026. Early CRB-913 data show a 2.9% placebo-adjusted mean weight loss at Day 14 with a favorable safety profile and no nausea or vomiting. With $177.8M in cash post-raise, CRBP is funded into 2028, mitigating near-term dilution risk. Read the full article on Seeking Alpha

Analiz Makalesi • Jul 07

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Mar 22

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...

Analiz Makalesi • Dec 06

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, Corbus...

Seeking Alpha • Nov 11

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Summary Corbus Pharmaceuticals still shows promise, with CRB-701 and CRB-601 advancing in clinical trials and CRB-913 targeting obesity with potentially fewer CNS side effects. Despite early-stage pipeline risks, CRBP's recent sell-off offers a favorable entry point for speculative investors, upgrading my rating from "Hold" to "Speculative Buy." CRBP's valuation is compelling with $159.4 million in liquidity and no significant debt, providing a healthy cash runway. Market concerns over CNS side effects from similar drugs may be overblown. CRB-913's design aims to avoid these issues, enhancing its blockbuster potential. CRB-913, a CB1 inverse agonist for obesity, aims to reduce CNS side effects and presents potential for combination therapy with GLP-1 agonists. Read the full article on Seeking Alpha

Seeking Alpha • Jan 30

Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug

Summary Positive results released from phase 1 China study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive solid tumors. Trial initiation of phase 1 study, using CRB-701 for the treatment of patients with metastatic urothelial carcinoma and other nectin-4 positive tumors, expected in Q1 of 2024. Additional results from the phase 1 China study, using CRB-701 for the treatment of patients with nectin-4 positive solid tumors, expected at medical meetings throughout 2024. Another ADC, known as PADCEV, is expected to generate $5 billion in projected revenues in urothelial carcinoma. Read the full article on Seeking Alpha

Seeking Alpha • Aug 09

Corbus Pharmaceuticals GAAP EPS of -$0.11

Corbus Pharmaceuticals press release (NASDAQ:CRBP): Q2 GAAP EPS of -$0.11. As of June 30, 2022, the Company has $74 million of cash and investments on hand which is expected to fund operations into the first quarter of 2024, based on the current planned expenditures.

Analiz Makalesi • Nov 19

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Hissedar Getirileri

	CRBP	US Biotechs	US Pazar
7D	-30.3%	1.3%	1.8%
1Y	6.6%	33.0%	28.4%

Getiri vs. Endüstri: CRBP geçen yıl % 33 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: CRBP geçen yıl % 28.4 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is CRBP's price volatile compared to industry and market?
CRBP volatility
CRBP Average Weekly Movement	14.6%
Biotechs Industry Average Movement	10.8%
Market Average Movement	7.2%
10% most volatile stocks in US Market	16.7%
10% least volatile stocks in US Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: CRBP hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.

Zaman İçindeki Volatilite: CRBP 'nin haftalık oynaklığı ( 15% ) geçen yıl boyunca sabit kaldı, ancak hala US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2009	36	Yuval Cohen	www.corbuspharma.com

Klinik aşamada bir şirket olan Corbus Pharmaceuticals Holdings, Inc. kanser ve obezite için terapötikler geliştirmekte ve ticarileştirmektedir. Boru hattı, monometil auristatin E'nin sitotoksik bir yükünü serbest bırakmak için kanser hücrelerinde Nectin-4 ekspresyonunu hedefleyen bir antikor ilaç konjugatı olan CRB-701'i ve obezite tedavisi için periferik olarak kısıtlanmış bir kannabinoid tip-1 reseptör ters agonisti olan CRB-913'ü içerir. Şirket 2009 yılında kurulmuştur ve merkezi Norwood, Massachusetts'tedir.

Corbus Pharmaceuticals Holdings, Inc. Temel Bilgiler Özeti

Corbus Pharmaceuticals Holdings'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
CRBP temel i̇stati̇sti̇kler
Piyasa değeri	US$135.51m
Kazançlar(TTM)	-US$84.53m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-1.7x

F/K Oranı

CRBP aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
CRBP gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$70.10m
Brüt Kâr	-US$70.09m
Diğer Giderler	US$14.43m
Kazançlar	-US$84.53m

Son Raporlanan Kazançlar

Mar 31, 2026

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-4.77
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

CRBP uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/29 22:54
Gün Sonu Hisse Fiyatı	2026/05/29 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Corbus Pharmaceuticals Holdings, Inc. 22 Bu analistlerden 9, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Kalpit Patel	B. Riley Securities, Inc.
Mayank Mamtani	B. Riley Securities, Inc.
George Zavoico	B. Riley Securities, Inc.

Corbus Pharmaceuticals Holdings (CRBP) Hisse Özeti

Ödüller

Risk Analizi

Corbus Pharmaceuticals Holdings, Inc. Rakipler

TriSalus Life Sciences

Arcturus Therapeutics Holdings

Canton Strategic Holdings

Tonix Pharmaceuticals Holding

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Corbus Pharmaceuticals Holdings, Inc. Reports Updated Clinical Data For CRB-701 Phase 1/2 Study In Oropharyngeal And Cervical Cancers

Corbus Pharmaceuticals Holdings, Inc. Appoints Nishant Saxena as Chief Business Officer

New minor risk - Share price stability

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

Corbus Pharmaceuticals Holdings Announces Updated Clinical Data From Phase 1/2 Study Of CRB-701 And Provides Update On CANYON-1 Phase 1b Study Of CRB-913

Price target decreased by 7.4% to US$39.00

Recent updates

Corbus Pharmaceuticals Holdings, Inc. Reports Updated Clinical Data For CRB-701 Phase 1/2 Study In Oropharyngeal And Cervical Cancers

Corbus Pharmaceuticals Holdings, Inc. Appoints Nishant Saxena as Chief Business Officer

New minor risk - Share price stability

We're Keeping An Eye On Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate

Corbus Pharmaceuticals Holdings Announces Updated Clinical Data From Phase 1/2 Study Of CRB-701 And Provides Update On CANYON-1 Phase 1b Study Of CRB-913

Price target decreased by 7.4% to US$39.00

Corbus Pharmaceuticals Holdings, Inc. Announces Updated Clinical Data for CRB-701 At ASCO 2026

Corbus Pharmaceuticals Holdings, Inc. Announces Last Patient First Visit in CANYON-1 Study of CRB-913 for the Treatment for Obesity

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Chief Medical Officer Dr. Dominic Smethurst, Effective June 30, 2026

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 13, 2026

New major risk - Revenue and earnings growth

Chief Medical Officer notifies of intention to sell stock

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals: Maintaining 'Hold' As Summer 2026 Obesity Data Catalyst Looms

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Alan Holmer from its Board of Directors, Effective December 31, 2025

Corbus Pharmaceuticals Holdings, Inc. Reports Results from Phase 1A Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity Demonstrating Favorable Safety Profile and Emerging Evidence of Weight Loss

New major risk - Shareholder dilution

Price target increased by 8.2% to US$44.00

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $74.999901 million.

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc. Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25

Corbus Pharmaceuticals Holdings Inc. to Present CRB-701 Phase 1/2 Data At ESMO 2025

Corbus Pharmaceuticals Holdings, Inc. to Host In-Person and Virtual KOL Event At ESMO 2025

FDA Grants Fast Track Designation to Corbus Pharmaceuticals' Nectin-4 Targeting ADC CRB -701 in Head and Neck Squamous Cell Carcinoma

Corbus Pharmaceuticals Announces Upcoming Presentation of Dose Expansion Phase 1/2 Clinical Data for Its Nectin-4 Targeting Adc CRB -701 At the 2025 ESMO Annual Congress

Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) In A Good Position To Deliver On Growth Plans?

Corbus Pharmaceuticals Holdings Inc. Initiates Multiple Ascending Dose Portion of Phase 1 Study of Highly Peripherally Restricted Cb1 Inverse Agonist Crb-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings, Inc.(NasdaqCM:CRBP) dropped from Russell 3000E Value Index

Corbus Pharmaceuticals Holdings, Inc. Announces First Patient Dosed with Its Nectin-4 Targeting ADC CRB-701 in Combination with Keytruda (Pembrolizumab)

Price target decreased by 7.2% to US$42.89

Corbus Pharmaceuticals Holdings, Inc. Announces Board Changes, Effective May 15, 2025

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 15, 2025

Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Is In A Good Position To Deliver On Growth Plans

Peter Salzmann Not to Stand for Re-Election as Director of Corbus Pharmaceuticals Holdings, Inc

Corbus Pharmaceuticals Holdings, Inc. Appoints Ian Hodgson as Chief Operating Officer

Consensus EPS estimates upgraded to US$4.32 loss

New minor risk - Market cap size

CEO & Director notifies of intention to sell stock

New minor risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Presents Phase 1 Dose-Escalation Study of Next-Generation Nectin-4 Targeting Antibody-Drug Conjugate CRB-701

Corbus Pharmaceuticals Holdings, Inc. Announces Clinical Data for CRB-701 from Western Dose Escalation Study to Be Presented at ASCO GU 2025

Corbus Pharmaceuticals Announces Dosing of First Patient in Its First-In-Human Study of CRB-601 to Treat Patients with Advanced Solid Tumors

Companies Like Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Are In A Position To Invest In Growth

Corbus Pharmaceuticals' CRB-701 Receives FDA Fast Track Designation for Metastatic Cervical Cancer Treatment

Price target decreased by 9.9% to US$56.78

Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies

Corbus Pharmaceuticals Holdings, Inc. Presents New CRB-913 Pre-Clinical Data At Obesity Week 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Enrollment Completion of Dose Escalation Stage of Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC (CRB-701)

Price target decreased by 13% to US$71.00

New major risk - Share price stability

Corbus Pharmaceuticals Holdings, Inc. Announces Board and Committee Changes

CEO & Director notifies of intention to sell stock

Corbus Pharmaceuticals Holdings, Inc., Annual General Meeting, May 16, 2024

Corbus Pharmaceuticals Holdings, Inc. Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

Corbus Pharmaceuticals Holdings, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New major risk - Negative shareholders equity

Corbus Pharmaceuticals Holdings, Inc. Appoints Dominic Smethurst as Chief Medical Officer

Corbus Pharmaceuticals Holdings, Inc. Announces Resignation of Rachael Brake, Ph.D., as Chief Scientific Officer, Effective from February 19, 2024

New major risk - Shareholder dilution

Corbus Pharmaceuticals Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $82.175 million.

New major risk - Shareholder dilution